Histamine H₃ receptor density is negatively correlated with neural activity related to working memory in humans.

Author(s)
Ito, Takehito; Kimura, Yasuyuki; Seki, Chie; Ichise, Masanori; Yokokawa, Keita; Kawamura, Kazunori; Takahashi, Hidehiko; Higuchi, Makoto; Zhang, Ming-Rong; Suhara, Tetsuya; Yamada, Makiko

Citation
EJNMMI Research (2018), 8

Issue Date
2018-06-14

URL
http://hdl.handle.net/2433/232643

Right
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Type
Journal Article

Textversion
publisher
Kyoto University
Histamine H₃ receptor density is negatively correlated with neural activity related to working memory in humans

Takehito Ito¹, Yasuyuki Kimura¹, Chie Seki¹, Masanori Ichise¹, Keita Yokokawa¹, Kazunori Kawamura², Hidehiko Takahashi³, Makoto Higuchi¹, Ming-Rong Zhang², Tetsuya Suhara¹ and Makiko Yamada¹*

Abstract

Background: The histamine H₃ receptor is regarded as a drug target for cognitive impairments in psychiatric disorders. H₃ receptors are expressed in neocortical areas, including the prefrontal cortex, the key region of cognitive functions such as working memory. However, the role of prefrontal H₃ receptors in working memory has not yet been clarified. Therefore, using functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) techniques, we aimed to investigate the association between the neural activity of working memory and the density of H₃ receptors in the prefrontal cortex.

Findings: Ten healthy volunteers underwent both fMRI and PET scans. The N-back task was used to assess the neural activities related to working memory. H₃ receptor density was measured with the selective PET radioligand [¹¹C] TASP457. The neural activity of the right dorsolateral prefrontal cortex during the performance of the N-back task was negatively correlated with the density of H₃ receptors in this region.

Conclusions: Higher neural activity of working memory was associated with lower H₃ receptor density in the right dorsolateral prefrontal cortex. This finding elucidates the role of H₃ receptors in working memory and indicates the potential of H₃ receptors as a therapeutic target for the cognitive impairments associated with neuropsychiatric disorders.

Keywords: Histamine H₃ receptor, Working memory, PET, fMRI
disease, while others found no beneficial effects examined by various drugs in different diseases [5]. These unclear therapeutic effects may come from the complex biology and pharmacology of H3 receptor, such as the heterogeneity of isoforms and the different profile of drug activity (full agonists, partial agonists, neutral antagonists, inverse agonists and protean ligands) [5].

Nevertheless, H3 receptors are highly expressed in the human cerebral cortex and basal ganglia, as revealed by autoradiographic studies of post-mortem brain tissue and by recent PET studies using radioligands targeting H3 receptors [3, 6]. Furthermore, a post-mortem brain sample study revealed that the prefrontal cortex of schizophrenia patients with cognitive impairments showed increased H3 receptor binding [7].

Thus, because the prefrontal cortex is the key region for working memory and H3 receptors are highly expressed in this region, the present study aimed to clarify whether brain activity related to working memory was associated with H3 receptor density in the prefrontal cortex. To accomplish this, we used fMRI as well as PET with the radioligand [11C] TASP457, which has high affinity and selectivity for H3 receptors [6, 8].

Methods
Participants
Ten right-handed (self-reported) healthy male volunteers (mean age ± standard deviation, 25 ± 4 years) participated in the study. All participants had no history of neurological and psychiatric disorders and were not taking any medications. The subjects underwent an fMRI with N-back task followed by a PET scan at rest, with the mean interval of 18.8 ± 20.6 days (mean ± standard deviation).

Radioligand preparation
The [11C] TASP457 precursor and standard used in this study were provided by Taisho Pharmaceutical Co., Ltd. [11C] TASP457 was radiosynthesised by O-alkylation of the 2-pirydone-containing precursor (desmethyl TASP457) with [11C] methyl triflate [4]. At a time of administration, the radiochemical purity of [11C] TASP457 was > 95%, and its specific activity was > 37 GBq/μmol.

PET procedures
After intravenous injection of [11C] TASP457 (390 ± 6 MBq with molar activity of 92 ± 32 GBq/μmol), we acquired three-dimensional dynamic images with a PET camera (Eminence SET-3000GCT/X, Shimadzu, Kyoto, Japan) for 120 min in 39 frames of increasing duration (from 10 s to 5 min). All PET images were reconstructed using the filtered back-projection method (Gaussian filter, kernel 5 mm; the reconstructed in-plane resolution was 7.5 mm in full width at half maximum (FWHM); voxel size 2 × 2 × 2.6 mm) corrected for attenuation, randoms, scatter and head motion. Plasma input functions were measured with arterial blood sampling and metabolite analyses using a radio high-performance liquid chromatography, as described previously [6].

fMRI procedures
We designed a modified version of the N-back task used in a previous study [2]. Participants responded to the numeric characters of previously seen stimuli according to three conditions, 0-, 1- and 2-backs.

A Siemens Verio 3 T MRI system (Siemens, Erlangen, Germany) was used to obtain T2*-weighted echo-planar imaging (repetition time [TR] = 2000 ms, echo time [TE] = 25 ms, slice number = 33 (interleaved), slice thickness = 3.7 mm, matrixes = 64 × 64, 345 volumes) with bold oxygen level-dependent (BOLD) contrasts and structural T1 image (TR = 2300 ms, TE = 1.95 ms, slice number = 176, slice thickness = 1 mm, matrixes = 256 × 256). Preprocessing analysis with SPM8 software (Wellcome Department of Cognitive Neurology, London, UK) included slice time correction, realignment, DARTEL normalisation and smoothing with a 6-mm FWHM Gaussian kernel. First-level analysis modelled the task as a block design, with working memory load as a linear regressor (0-back = −1, 1-back = 0, 2-back = 1). Six realignment parameters and two derivatives were used as covariates. Artefacts in fMRI time series data were detected and corrected using robust weighted least squares [9]. A mask image of the prefrontal cortex (including Brodmann areas 8, 9, 10, 11, 12, 13, 14, 24, 25, 32, 44, 45, 46 and 47) was created using WFU PickAtlas 3.0.5 software (Wake Forest University, Winston-Salem, NC). Group-level random effect analysis was performed to identify the activity corresponding to increased working memory load within the prefrontal cortex, using a threshold of P < 0.001 (uncorrected) with a minimum cluster size of 20 voxels [10]. Age was included as a nuisance covariate.

PET and fMRI analyses
The contrast coefficients (β value) were extracted from the cluster images of increased working memory load. Time–activity curves were generated using data extracted from the PET images by applying the spherical (radius 4 mm) regions of interest images centred on the peak coordinates of each cluster. Total distribution volume (VT), which reflects the H3 receptor density in the brain, was calculated using Ichise’s multilinear analysis (MA1) [11] with the time–activity curves for the initial 60 min and plasma input functions according to the previous quantitative analysis of [11C] TASP457–PET data [6]. The correlation analyses between MRI (β value) and
PET ($V_T$) data were conducted with IBM SPSS Statistics, version 23 (IBM Corp., Armonk, NY). To compensate for the small sample size, we used a resampling procedure based on 5000 bootstrapped samples, using bias-corrected and accelerated (BCa) 95% confidence intervals (CIs) to estimate Pearson’s correlation coefficient for the neural activity and $V_T$.

**Results**

**Behavioural data**

There were no significant differences in accuracy across the three $N$-back tasks (0-back, 98.0 ± 0.7%; 1-back, 98.1 ± 0.8; 2-back, 97.1 ± 1.1; Friedman test $P = 0.66, \chi^2 = 0.84, df = 2$). The performances of 1- and 2-backs showed the ceiling effects as they were not significantly different from the maximum accuracy of 100% (Wilcoxon signed-rank tests both $P_s > 0.05$, both $W_s = −15$); thus, the behavioural data were not used for further analyses to avoid spurious estimates.

**Imaging data**

Three clusters, in which neural activities assessed by fMRI were associated with increased working memory load, were detected in the bilateral DLPFC (the left middle frontal gyrus, left superior frontal gyrus and right middle frontal gyrus; Table 1). Their $V_T$ values (mL/cm$^3$), estimated from PET data, were 7.4 ± 0.6 for the left middle frontal gyrus, 7.2 ± 0.9 for the left superior frontal gyrus and 7.0 ± 0.6 for the right middle frontal gyrus. The $\beta$ value of the right middle frontal gyrus (Fig. 1a) was negatively correlated with the $V_T$ value of this region (Spearman $r = −0.65, P = 0.043, 95\%$ BCa CI = ($−0.91, −0.05$), bias = 0.063, standard error = 0.21, Fig. 1b). No significant correlations were found in the other two clusters.

**Discussion**

The present study revealed that higher activity in the right DLPFC due to increased working memory load, which was consistent with the findings of previous studies [1, 2], was associated with lower density of H$_3$ receptors. Preclinical studies demonstrated that H$_3$ receptor blockade with H$_3$ antagonists increased the release of neurotransmitters such as acetylcholine and dopamine, resulting in enhanced cognition, whereas H$_3$ agonists impaired cognition [3]. Enhanced cognition has also been reported in H$_3$ receptor knockout rodents [3]. Thus, the individual variability of H$_3$ receptor density may reflect the ability of neurotransmitter release. Taken together with our findings, these results indicate that inhibition of H$_3$ receptors, which increases the release of histamine and other neurotransmitters, plays a role in working memory activation in the right DLPFC.

Although very few studies have investigated the role of H$_3$ receptors in working memory in humans, one fMRI study revealed that an increase in histamine neurotransmission induced by betahistine (H$_3$ antagonist/H$_1$ agonist) moderately increased right DLPFC activity during $N$-back task performance [12]. This finding also supports the role of the H$_3$ receptor

---

**Table 1** Neural activity as a function of increased working memory load

| Region                  | Side | BA   | Cluster size | Z value  | x   | y   | z   |
|-------------------------|------|------|--------------|----------|-----|-----|-----|
| Middle frontal gyrus    | Left | 9    | 83           | 3.91     | −28 | 32  | 34  |
| Superior frontal gyrus  | Left | 8    | 45           | 3.53     | −26 | 8   | 60  |
| Middle frontal gyrus    | Right| 8    | 21           | 3.33     | 28  | 10  | 60  |

$s, y, z$ corresponds to Montreal Neurological Institute (MNI) coordinates

BA Brodmann area

---

![Fig. 1a](image1a.png) Group map showing the activity in the right middle frontal gyrus (red, $x, y, z = 28, 10, 60$) in response to increased working memory load. **b** The activity in the right middle frontal gyrus was negatively correlated with the H$_3$ receptor radioligand retention ($V_T$), which reflects the H$_3$ receptor density. The dashed lines indicate 95% confidence intervals. The PET image on the graph indicates the distribution of the H$_3$ receptors in the brain. The sagittal image was obtained by averaging parametric images of the 10 subjects. The parametric images were calculated using Ichise’s multilinear analysis to estimate total distribution volume for each voxel and spatially normalised thereafter. The circle indicates the location of the activated region detected in fMRI during performing working memory task in the right middle frontal gyrus shown in **a**
inhibition in DLPFC activation, consistent with our study results.

One of the key limitations of this study is its small sample size, which decreased its statistical power. Moreover, we were unable to establish a causal relationship between H3 receptor density and working memory activity in the DLPFC or to examine the association between H3 receptors and working memory performance. Further studies with a larger sample size and the use of H3 agonists/antagonists are required to establish the causal relationship between H3 receptors and working memory activity and its performance.

Conclusion
In conclusion, the present study showed for the first time that H3 receptor density was associated with working memory activity in the right DLPFC in humans, revealing a histaminergic mechanism underlying working memory. This finding supports the potential of histaminergic modulators, especially those that affect H3 receptors, for treating cognitive impairments in neuropsychiatric disorders.

Acknowledgements
We thank the radiology technologists of the PET Department and members of the Brain Disorder Translational Research Team for their support with PET scans, Kazuko Suzuki and Shizuko Kawakami for their assistance as clinical coordinators, Hiromi Sano for her support with MRI scans, the staff of the Department of Radiopharmaceuticals Development for radioligand synthesis and metabolite analysis, and Atsuo Waki and his team for quality assurance of the radioligand. The [11C] TASP457 precursor and standard used in this study were provided by Taisho Pharmaceutical Co., Ltd.

Funding
This research was partly supported by JSPS KAKENHI grant numbers 15K11958, 16K05164, 17K16586, and 18K19215 and by AMED under grant numbers JP18dm0107094 and JP18dm027007.

Availability of data and materials
Please contact the author for data requests.

Authors’ contributions
All authors contributed substantially to the scientific process leading to this manuscript. Authors TI, YK and M Y contributed to the design of the study. Authors TI, YK, CS and KY acquired data. KK and MRZ prepared the PET study. Authors TI, YK, CS and MY performed the data analyses. TI, YK and MY drafted the manuscript. HT, MH and TS critically contributed to the manuscript. All authors contributed substantially to the scientific process leading to this manuscript.

Ethics approval and consent to participate
This study was approved by the Radiation Drug Safety Committee and the Institutional Review Board of National Institute of Radiological Sciences of Japan. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.

Competing interests
YK, MH, and TS are involved in a joint research and clinical trial sponsored by Taisho Pharmaceutical Co., Ltd. MH and TS hold a patent for [11C] TASP457 and related chemicals as H3 ligands (Japan patent JP2014-47209A).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References
1. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005;25:46–59.
2. Callcott JH, Mattay VS, Bertolino A, Finni K, Coppola R, Frank JA, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex. 1999;9:20–6.
3. Esbenshade TA, Browman KE, Briner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol. 2008;154:1166–8.
4. Sadek B, Saad A, Saadeg A, Jalal F, Stark H. Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res. 2016;312:415–30.
5. Łazewska D, Kiel-Kononowicz K. Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013–2017). Expert Opin Ther Pat. 2018;28:175–96.
6. Kimura Y, Seki C, Ikoma Y, Ichise M, Kawamura K, Takahata K, et al. [11C] TASP457, a novel PET ligand for histamine H3 receptors in human brain. Eur J Nucl Med Mol Imaging. 2016;43:1653–63.
7. Jin CY, Anichtchik O, Panula P. Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol. 2009;157:118–29.
8. Koga K, Maeda J, Tokunaga M, Hanyu M, Kawamura K, Ohtsuki M, et al. Development of TASP0410457 (TASP457), a novel dihydroquinolinolone derivative as a PET radioligand for central histamine H3 receptors. JNMWRI. 2016;61:11.
9. Diederichsen J, Shadmehr R. Detecting and adjusting for artifacts in fMRI time series data. NeuroImage. 2005;27:624–34.
10. Woo C-W, Krishnan A, Wager TD. Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations. NeuroImage. 2014;91:412–9.
11. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002;22:1271–81.
12. Van Ruitenbeek P, Mehta MA. Potential enhancing effects of histamine H4 agonism/H3 antagonism on working memory assessed by performance and bold response in healthy volunteers. Br J Pharmacol. 2013;170:134–55.